Literature DB >> 20585723

Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006.

Rosalba Rojas1, Carlos A Aguilar-Salinas, Aída Jiménez-Corona, Teresa Shamah-Levy, Juan Rauda, Leticia Avila-Burgos, Salvador Villalpando, Eduardo Lazcano Ponce.   

Abstract

OBJECTIVE: To examine the prevalence of metabolic syndrome (MS) and its associated risk factors in Mexican adults aged 20 years or older, using data derived from the National Health and Nutrition Survey 2006 (ENSANUT 2006).
MATERIAL AND METHODS: The ENSANUT 2006 was conducted between October 2005 and May 2006. Questionnaires were administered to 45 446 adult subjects aged 20 years or older who were residents from urban and rural areas. Anthropometric and blood pressure measurements were obtained from all subjects and fasting blood specimens were provided by 30% of participants. We randomly selected a sub-sample of 6 613 from which laboratory measurements were carried out for glucose, insulin, triglycerides, total cholesterol and HDL-cholesterol. For this analysis, we included only results from eight or more hours of fasting samples (n=6 021). We used individual weighted factors in the statistical analysis and considered the survey's complex sampling design to obtain variances and confidence intervals. All analyses were done using SPSS 15.0.
RESULTS: In accordance with definitions by the National Cholesterol Education Program Adult Treatment Panel III (ATP III), the American Heart Association/National Heart, Lung and Blood Institute (AHA/NHLBI), and the International Diabetes Federation (IDF), the prevalence of MS in Mexican adults aged 20 years or older was 36.8, 41.6 and 49.8%, respectively. Women were more affected than men due to the higher prevalence of central obesity among females. Prevalence of MS increased with age and was higher among populations living in metropolitan areas, in the west-central region, and those with lower education. DISCUSSION: Regardless of the MS definition, a large proportion of Mexican adults has the condition, so preventive measures are needed to decrease the prevalence of the MS components in this population. MS can predict type 2 diabetes and cardiovascular disease, two of the main causes of death in the adult population in Mexico. The intentional search of MS components allows stratifying the population according to risk levels. Treatment for each component should be implemented properly to prevent or delay onset of type 2 diabetes and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20585723     DOI: 10.1590/s0036-36342010000700004

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  47 in total

1.  Serum leptin is associated with metabolic syndrome in obese Mexican subjects.

Authors:  Sara García-Jiménez; German Bernal Fernández; Maria Fernanda Martínez Salazar; Antonio Monroy Noyola; Cairo Toledano Jaimes; Angelica Meneses Acosta; Leticia Gonzalez Maya; Elizabeth Aveleyra Ojeda; Maria A Terrazas Meraz; Marie-Catherine Boll; Miguel A Sánchez-Alemán
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 2.  Pharmacological treatment and therapeutic perspectives of metabolic syndrome.

Authors:  Soo Lim; Robert H Eckel
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

3.  Socioeconomic status, psychosocial resources and risk, and cardiometabolic risk in Mexican-American women.

Authors:  Linda C Gallo; Addie L Fortmann; Scott C Roesch; Elizabeth Barrett-Connor; John P Elder; Karla Espinosa de los Monteros; Smriti Shivpuri; Paul J Mills; Gregory A Talavera; Karen A Matthews
Journal:  Health Psychol       Date:  2011-11-07       Impact factor: 4.267

4.  Does metformin increase paraoxonase activity in patients with the metabolic syndrome? Additional data from the MEFISTO study.

Authors:  Eduardo Meaney; Patricia Sierra-Vargas; Alejandra Meaney; Martín Guzmán-Grenfell; Israel Ramírez-Sánchez; Juan Jose Hicks; Ivonne Olivares-Corichi; Guillermo Ceballos
Journal:  Clin Transl Sci       Date:  2012-06       Impact factor: 4.689

5.  Associations between socioeconomic status and catecholamine levels vary by acculturation status in Mexican-American women.

Authors:  Jessica A Jiménez; Smriti Shivpuri; Karla Espinosa de los Monteros; Karen A Matthews; Paul J Mills; Linda C Gallo
Journal:  Ann Behav Med       Date:  2012-08

6.  Effect of a High-Protein Diet versus Standard-Protein Diet on Weight Loss and Biomarkers of Metabolic Syndrome: A Randomized Clinical Trial.

Authors:  Ismael Campos-Nonato; Lucia Hernandez; Simon Barquera
Journal:  Obes Facts       Date:  2017-06-10       Impact factor: 3.942

7.  Longitudinal association of obesity, metabolic syndrome and diabetes with risk of elevated aminotransferase levels in a cohort of Mexican health workers.

Authors:  Yvonne N Flores; Allyn Auslander; Catherine M Crespi; Michael Rodriguez; Zuo-Feng Zhang; Francisco Durazo; Jorge Salmerón
Journal:  J Dig Dis       Date:  2016-05       Impact factor: 2.325

8.  Associations between nocturnal blood pressure dipping and the metabolic syndrome in high- vs. low-acculturated Mexican American women.

Authors:  Smriti Shivpuri; Matthew A Allison; Caroline A Macera; Suzanne Lindsay; Linda C Gallo
Journal:  Am J Hypertens       Date:  2013-05-03       Impact factor: 2.689

9.  Association between the Use of Health Services, Cardiovascular Risk Factors and Metabolic Syndrome in Mexican Adults.

Authors:  María Araceli Ortiz-Rodríguez; María Vanessa Aldaz-Rodríguez; Luz María González-Robledo; Antonio Villa; Cristina Bouzas; Rosario Pastor; Josep A Tur
Journal:  Int J Environ Res Public Health       Date:  2021-05-17       Impact factor: 3.390

10.  Polymorphisms in Genes Involved in the Leptin-Melanocortin Pathway are Associated with Obesity-Related Cardiometabolic Alterations in a Southern Chilean Population.

Authors:  Victor Manriquez; Jorge Aviles; Luis Salazar; Nicolas Saavedra; Pamela Seron; Fernando Lanas; Cristina Moreno Fajardo; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata; Alvaro Cerda
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.